AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.
AstraZeneca closed 9% down on an unconfirmed report of Bristol Myers talks. Roughly $24bn gone, on a conversation neither company will admit to.
The Beats
Analysis
The Briefs
AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.
Pathos Put 6% Down on a Phase III ADC, and Alphamab Kept the Market It Can Actually Reach
Dr. Reddy’s Developed, Made and Filed the Rituximab. Fresenius Only Sells It.
The 340B Rebate Pilot Is Back at Under 5.5% of Sales, Rebuilt to Survive the Court That Killed It
KKR’s 51.8% Premium for Integer Is Measured From Before the Company Said It Was for Sale